Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02188173 · ClinicalTrials.gov registry record
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 200
- Enrollment target
NCT02188173: Completed study, sponsored by Allergan.
NCT02188173 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02188173 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
Interventions
- DRUG dexamethasone 700 ㎍ intravitreal implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-05 |
What the finished NCT02188173 record still lists
NCT02188173 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which dexamethasone 700 ㎍ intravitreal implant is the first listed.
NCT02188173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02188173 about?
NCT02188173 is a clinical study titled "An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)". This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
What is the current status of trial NCT02188173?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2014-07. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02188173?
The interventions under investigation include: dexamethasone 700 ㎍ intravitreal implant (DRUG).
Who is sponsoring clinical trial NCT02188173?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia